BDBM304441 (R)-5-(4-(5-acetyl-4-(trifluoromethyl)pyrimidin-2-yl)-3-isopropylpiperazin-1-yl)-2-fluoro-N-methylbenzenesulfonamide::US10144715, Compound 13-2
SMILES: CNS(=O)(=O)c1cc(ccc1F)N1CCN([C@@H](C1)c1ccc(F)cc1)c1ncc(C(C)=O)c(n1)C(F)(F)F
InChI Key: InChIKey=MXGAWJHHWQSRGH-FQEVSTJZSA-N
Data: 1 KI
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Oxysterols receptor LXR-beta (Homo sapiens (Human)) | BDBM304441 ((R)-5-(4-(5-acetyl-4-(trifluoromethyl)pyrimidin-2-...) | UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 3 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Vitae Pharmaceuticals, Inc. US Patent | Assay Description Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan... | US Patent US10144715 (2018) BindingDB Entry DOI: 10.7270/Q2PV6NFD | |||||||||||
More data for this Ligand-Target Pair |